AGENDA
Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:
1. Call To Order
   A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:
2. Public Comment Forum
   A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:
3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A
   A. September 11, 2013 DUR Minutes – Vote
   B. September 11, 2013 DUR Recommendation Memorandum
   C. October 9, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:
4. Action Item – Vote on 2014 Meeting Dates – See Appendix B

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:
5. Action Item – Update on DUR / Medication Coverage Authorization Unit / Safety Alerts and 30 Day Notice to Prior Authorize Ketoconazole Oral Tablets – See Appendix C
   A. Medication Coverage Activity for October 2013
   B. Pharmacy Help Desk Activity for October 2013
   C. Valproate Product Update
   D. Ketoconazole Safety Communication and 30 Day Notice to Prior Authorize Ketoconazole Oral Tablets
   E. Update on Safety Alerts

Items to be presented by Dr. Le, Dr. Muchmore, Chairman
6. Annual Review of Botulinum Toxins – See Appendix D
   A. Current Prior Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. Market News and Updates
   E. COP Recommendations
Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

7. **Annual Review of Prenatal Vitamins – See Appendix E**
   A. Current Prior Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. COP Recommendations
   E. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

8. **Annual Review of Antihypertensive Medications and 30 Day Notice to Prior Authorize Epaned™ – See Appendix F**
   A. Current Prior Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. Market News and Updates
   E. Product Summary
   F. COP Recommendations
   G. Utilization Details
   H. Product Details

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman

9. **Annual Review of Nasal Allergy Medications and 30 Day Notice to Prior Authorize Zetonna® – See Appendix G**
   A. Current Prior Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. Market News and Updates
   E. COP Recommendation
   F. Utilization
   G. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

10. **Annual Review of Glaucoma Medications and 30 Day Notice to Prior Authorize Simbrinza™ and Rescula® – See Appendix H**
    A. Current Prior Authorization Criteria
    B. Utilization Review
    C. Prior Authorization Review
    D. Market News and Updates
    E. COP Recommendation
    F. Utilization Details
    G. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

11. **Annual Review of Pediculicides and 30 Day Notice to Prior Authorize Sklice® – See Appendix I**
    A. Current Prior Authorization Criteria
    B. Utilization Review
    C. Prior Authorization Review
    D. Market News and Updates
    E. COP Recommendations